You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINETM molecule that releases fully potent IL-2 in the tumor microenvironment

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINETM molecule that releases fully potent IL-2 in the tumor microenvironment

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Nirschl CJ, Brodkin HR, Hicklin DJ, et al
1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINETM molecule that releases fully potent IL-2 in the tumor microenvironment
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1058